Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00557115" target="_blank" >RIV/61388963:_____/22:00557115 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/s13311-022-01228-5" target="_blank" >https://doi.org/10.1007/s13311-022-01228-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13311-022-01228-5" target="_blank" >10.1007/s13311-022-01228-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

Popis výsledku v původním jazyce

One of the greatest challenges with successful pharmaceutical treatments of central nervous system (CNS) diseases is the delivery of drugs into their target sites with appropriate concentrations. For example, the physically tight blood-brain barrier (BBB) effectively blocks compounds from penetrating into the brain, also by the action of metabolizing enzymes and efflux transport mechanisms. However, many endogenous compounds, including both smaller compounds and macromolecules, like amino acids, sugars, vitamins, nucleosides, hormones, steroids, and electrolytes, have their peculiar internalization routes across the BBB. These delivery mechanisms, namely carrier-mediated transport and receptor-mediated transcytosis have been utilized to some extent in brain-targeted drug development. The incomplete knowledge of the BBB and the smaller than a desirable number of chemical tools have hindered the development of successful brain-targeted pharmaceutics. This review discusses the recent advancements achieved in the field from the point of medicinal chemistry view and discusses how brain drug delivery can be improved in the future.

Název v anglickém jazyce

Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics

Popis výsledku anglicky

One of the greatest challenges with successful pharmaceutical treatments of central nervous system (CNS) diseases is the delivery of drugs into their target sites with appropriate concentrations. For example, the physically tight blood-brain barrier (BBB) effectively blocks compounds from penetrating into the brain, also by the action of metabolizing enzymes and efflux transport mechanisms. However, many endogenous compounds, including both smaller compounds and macromolecules, like amino acids, sugars, vitamins, nucleosides, hormones, steroids, and electrolytes, have their peculiar internalization routes across the BBB. These delivery mechanisms, namely carrier-mediated transport and receptor-mediated transcytosis have been utilized to some extent in brain-targeted drug development. The incomplete knowledge of the BBB and the smaller than a desirable number of chemical tools have hindered the development of successful brain-targeted pharmaceutics. This review discusses the recent advancements achieved in the field from the point of medicinal chemistry view and discusses how brain drug delivery can be improved in the future.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurotherapeutics

ISSN

1933-7213

e-ISSN

1878-7479

Svazek periodika

19

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

35

Strana od-do

942-976

Kód UT WoS článku

000779225400001

EID výsledku v databázi Scopus

2-s2.0-85128867471